Behzad has over 25 years of experience in the biopharmaceutical industry, with 15 years of experience as an institutional investor. He currently serves as Managing Partner and Portfolio Manager of Avoro Capital Advisors, LLC, an SEC registered investment manager investing across the life sciences spectrum, in both public equity and private market opportunities.

Behzad began his career in healthcare as a research scientist, later joining Booz Allen as a management consultant, where he led major strategic and operational initiatives for companies in the pharmaceutical and biotechnology industries. Behzad served as the Chairman of Immunomedics, a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of cancers and other diseases with high unmet medical need, until the company’s $21B acquisition by Gilead in 2020. He currently serves on the board of Scribe Therapeutics, Inc., a private molecular engineering company developing advanced technologies for CRISPR-based genetic medicine, as well as the board of Aadi Bioscience, a biopharmaceutical company focusing on precision therapies for genetically-defined mTOR pathway genes.

Behzad received his Master’s degree in Physics from the Ludwig-Maximilians-University (Munich, Germany) and a PhD from Cornell University in Biochemistry & Biophysics.